On 12 February 2015, orphan designation (EU/3/15/1448) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase for the treatment of facioscapulohumeral muscular dystrophy.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in January 2020 on request of the Sponsor.
EU/3/15/1448: Public summary of opinion on orphan designation: 505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase for the treatment of facioscapulohumeral muscular ... (PDF/217.2 KB)
First published: 09/04/2015
Last updated: 09/04/2015
505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase
|Disease / condition||
treatment of facioscapulohumeral muscular dystrophy
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.